Marseille (France), October3rd 2006 -- Pharmaxon, the Marseille-based emerging
biopharmaceutical company specializing in the discovery and development of
innovative drugs for nervous system disorders, today announced the completion of
a seed financing round of over half a million euros. The funds will accelerate
preclinical development of the company's ongoing programs. A number of respected
investors (Inserm Transfert Initiative, Esperante, Primaveris and CAAP Création, a
subsidiary of Crédit Agricole Alpes Provence) participated in various ways in the
funding round, with the first three taking an equity stake in Pharmaxon.
